Kinase enzymes are involved in a vast array of biological processes associated with human disease; therefore, selective kinase inhibition by small molecules and therapeutic antibodies is an area of intense study. The authors show that drug candidates with immediate value for biological preclinical evaluation can be identified directly through ultra-efficient affinity screening of kinase enzymes and random compound mixtures. The screening process comprises sampling and trapping equilibrium binding between candidate ligands and protein in solution, followed by removal of unbound ligands via 3 rounds of ultrafiltration and direct identification of bound ligands by mass spectrometry. Evaluation of significant peaks is facilitated by automated integration and collation of the mass spectral data and import into custom software for analysis. One Chk1-selective ligand found by using this process is presented in detail. The compound is potent in both enzymatic and Chk1-dependent cellular assays, and specific contacts in the Chk1 active site are shown by X-ray crystallography. (Journal of Biomolecular Screening 2006:755-764) 
INTRODUCTION
R EVERSIBLE PHOSPHORYLATION OF PROTEINS plays a key role in virtually all aspects of cell life. 1, 2 Slightly more than 500 kinases have been identified in the human genome, 3 and both academic and industrial research laboratories are striving to understand the role of each kinase enzyme in normal and disease-related function. Although small-molecule drug discovery is most often emphasized by the industrial sector for developing orally active drugs for disease treatment, soluble small organic molecules also are proving to be useful research tools in academia and industry for elucidating the function of kinase targets in signal transduction pathways. 4 Rapid methods for identification of small-molecule kinase enzyme inhibitors are needed for drug discovery, for validation of target kinases as disease targets, and for elucidation of function in signal transduction pathways.
Several factors currently impede the rapid identification of specific chemical probes. First, the expense and time required for a high-throughput screening (HTS) campaign typically limits an organization to examining a small number of kinase enzymes per year. Second, high intracellular adenosine triphosphate (ATP) concentrations and structural similarity in the active site among kinases 5, 6 raise the difficulty level for generating potency and specificity quickly. Several recent kinase inhibitor examples that have shown success in the clinic, however, point to the possibilities that exist for achieving selectivity through allosteric binding outside the active site or to the active site region of an inactive protein form. 7, 8 Although these success stories were developed from weak hits in activity-based screens, affinity-based screening of multiple kinases provides a rational strategy for simultaneous comparison of chemical compound classes without a bias toward active site inhibitors. A further advantage of some affinitybased HTS techniques is that the comparative data for the different targets are not compromised by differences in the screening assays (e.g., ATP and substrate concentrations relative to K m , substrate composition, and incubation time), as the conditions of each affinity screen can be made identical. 9 Chk1, a serine/threonine kinase, is a key cell cycle checkpoint protein and important cancer drug discovery target. [10] [11] [12] [13] [14] Chk1 functions at the G2 checkpoint of the cell cycle to phosphorylate and thereby inactivate Cdc25C phosphatase so that Cdc25C does not activate Cdc2. When Chk1 phosphorylates Cdc25C at S216, the latter is able to bind to 14-3-3 proteins, which then shuttle the Cdc25C protein out of the nucleus in response to damage. When Chk1 is inhibited, Cdc25C remains unphosphorylated, does not bind 14-3-3 proteins, and is not shuttled out of the nucleus. When DNA damage occurs, nuclear Cdc25C is able to activate the target Cdc2 cyclin-dependent kinase by dephosphorylation at T14 and Y15 and thereby promote mitosis by abrogating the G checkpoint. Under normal conditions, the activity of Chk1 allows cell cycle arrest after DNA damage, which allows time for DNA repair. When Chk1 is inhibited and mitosis is promoted via the dual-specificity phosphatase activity of Cdc25C, the DNA damage is not repaired and apoptosis occurs. Compared to other chemotherapeutic agents, Chk1 inhibitors should have low cytotoxicity on their own yet be able to enhance the efficacy of DNA-damaging drugs such as doxorubicin. 12 Here we describe application of a simple affinity screening methodology with the capacity to screen large numbers of compounds and targets with mass spectrometric readout that merely requires soluble protein and a commercial ultrafiltration device. Multiple kinase enzymes were rapidly cloned, expressed, and purified by standard techniques. The enzymes then were validated for use in affinity selection/mass spectrometry (ASMS) screening by examination of a panel of commercial commonly used protein kinase inhibitors, screened by using the ASMS technique, and ligands were confirmed by enzymatic assay. Both ubiquitous and novel ligand series were characterizedfor Chk1.
RESULTS

Affinity screening process
The general method for ASMS was carried out as described (see accompanying article by Comess et al 15 ). In the first step, a very large mixture of candidate ligands is allowed to reach solution-binding equilibrium with the target macromolecule, typically a protein, under conditions where the target is presented in excess concentration over individual ligands. Thus, the amount of compound bound at equilibrium is related to both the intrinsic K D and the protein concentration. Ultrafiltration next is used to separate ligands associated with the protein from nonligands free in solution. The initial volume of 400 µL is reduced to 40 µL. Because a large number of candidate ligands are included in the initial equilibrated solution, a single round of 10-fold concentration is not sufficient to enrich ligands over the nonligands. To further reduce the chemical background, multiple rounds of dilution, reequilibration, and filtration are carried out. A total of 3 rounds of selection were used to increase the signal for ligands over background of nonligands. The ratio of the protein concentration to the K D determines the amount of compound retained per round of selection, and the enrichment of stronger ligands relative to weaker ligands and nonligands increases with successive rounds of selection. Finally, the protein is denatured, and compounds are identified directly by mass spectrometry. A single distinct peak in a mass spectrum typically corresponds to more than 1 possible small molecule, due to mass redundancy in the large random compound mixtures.
For the second phase of testing, compounds picked from the primary screens are physically remixed from single-compound liquid stocks into pools of 10 to 30 compounds with the monoisotopic molecular weights distributed among the smaller pool mixtures to remove any mass redundancy and ambiguity in ligand identification. These mixtures contain a highly enriched population of ligands compared to primary screening mixtures. The reduced mixture size is necessary to prevent competition for limited protein binding sites in the enriched library. Although the pick rate for the primary stage of screening is very low, averaging less than 1% (see below), the expected hit rate at the retest stage is high. Based on successful deconvolution of 50% of the peaks, an average number of compounds per peak of 6, and an average result of 1 confirmed ligand per primary peak successfully deconvoluted, the hit rate from the second phase is anticipated to be 8%. This strategy of a large mixture size at the start and a small mixture size at the retesting phase typically results in a high rate of confirmed ligands at the end of screening ( Table 1 ). Figure 1 graphically displays mass spectrometric peaks selected for a target across several different large pool mixtures, together with the compounds that deconvolute from these picked peaks. The data illustrate typical mass redundancy, confirmation rates, and confirmed ligands per pick. If a high background of false positives due to compounds with high response factors (i.e., very high intrinsic mass spectrometric ionization sensitivity) were found, the confirmation rates would be unacceptably low. Three rounds of selection reduce the background sufficiently to achieve a high confirmation rate (low false-positive rate).
For the ASMS screens of kinase targets, a custom automated hit selection program was used. This program allows multiple adjustable parameters to be set so that hits with measurable response factors in the mass spectrometer can be compared. The signal intensity and local background for a given ligand depend on the intrinsic sensitivity (i.e., ionizability) of the compound, its affinity for the protein target, its mass/charge (m/z) ratio, and the other ligands present in the mixture. Because the readout for this HTS format is nonuniform, a simple intensity cutoff cannot be used. The hit selection program is able to consider the height of a peak in relation to its neighboring peaks both in the same spectrum and in other spectra, in order to normalize against noisy parts of the spectrum and normalize against background peaks that might occur in every spectrum at the same m/z position. By empirical analysis of multiple screens, parameters were established that discriminate for peaks that stand out from the chemical background and background due to instrument noise at all m/z positions. Figure 2 shows several software views of primary screening data for Chk1 and includes the identities of 3 compound leads subsequently deconvoluted. The peaks that yield ligands often are not obvious picks in the mass spectra (e.g., Fig. 2C ), but they meet empirically established criteria for selection of ligands. These comprise the following:
1. Intrapool criterion: the signal of the peak is greater than 3-fold above the median of the intensities of all peaks within 10 m/z units of the peak of interest in the same spectrum; 2. Interpool criterion: the signal of the peak is greater than 3-fold above the median of the intensities of all peaks in the included sample files at the same m/z and ion detection mode (graphically illustrated in Figure 2B) ; and 3. m/z tolerance criterion: the m/z position of the peak must be within 0.1 atomic mass units (amu) of at least 1 compound in the compound pool mixture.
The ASAE.NET software is able to pick appropriate peaks much more rapidly than picking by eye and is also capable of discriminating small but relevant peaks. The increased speed and accuracy of picking was coupled with further automation in electronic data entry and segregation of putative hits by exact mass, order to reduce the time between primary screening and the next step, retesting and deconvolution of the hits. Compounds of varying mass in a mixture are detected to an accuracy of 0.1 amu. The readout is redundant for multiple compounds to some extent, however, as some compounds in a single mixture may have the same mass. The mass spectra of solventextracted samples are analyzed by software to match significant peaks to lists of the expected positions of compounds within the candidate ligand mixtures. Although there is a possibility for significant peak distortion and loss of accuracy due to multiple compounds presenzt at the same mass, the tolerance criteria of 0.1 m/z units allow for the peak still to be picked.
A collection of commercially available kinase inhibitors was used to provide validation of targets expressed and purified for the screening campaigns. Nine target examples are shown in Table 2 . The compounds chosen for study are not reported to be especially selective but were chosen simply to distinguish that the active site was competent under the conditions of ASMS screening. 2 These were mixed with target proteins and subjected to selection procedures identical to those for primary screening. Quantitative and qualitative comparison of R0 (stage prior to first round of screening) and R3 (stage at end of 3 rounds of affinity selection) mass spectra affords the 3 scoring categories shown. Staurosporine binds to every kinase tested ( Table 2 ) but no nonkinase targets (data not shown). Because the K i value of staurosporine is in the low nanomolar range for several of the targets shown, these data also illustrate that the solvent extraction procedure is able to dissociate tight interactions. The set of results for control compounds illustrates that each of the kinase targets is able to bind 1 or more of the control compounds. Nonkinase targets fail to show binding to these compounds (data not shown).
Mixture size study
To maximize the efficiency of the screening process, in terms of reducing both protein consumption and time spent at the bench, we wished to use primary screening mixtures of very large size. In the course of developing the screening methodology, we created mixtures as small as 720 compounds and as large as 3000 compounds. Compounds 1, 2, and 3 are present in mixtures of several different sizes. These mixtures were used for analysis of mixture size-based suppression effects. A diverse subset of 8640 compounds was screened in 12 mixtures of 720 compounds each mixture, as well as in 8 mixtures of 1080 compounds each mixture. All 20 mixtures were run in duplicate. The rest of the library (229,157 compounds) was screened in duplicate in 86 mixtures of 1800 to 3000 compounds. A total of 36 unique compounds (0.4% of the library) were selected for retesting and deconvolution from the subset mixtures. For the larger library, 1913 compounds were picked in 1 replicate and 2358 compounds picked in the other replicate, and the 712 compounds that were picked in both replicates were parsed to 30 nonmass redundant mixtures of approximately 24 compounds each. Compound 1 ( Fig. 2A, B ) was present in a mixture of 2400 compounds, in both replicates. The compound was identified as a hit in the negative ionization mode. The compound was not present in the 8640compound subset library. Compound 2 was present in both the subset library and 2 different main library mixtures. In the positive ionization mode, compound 2 was identified in 7 of 8 opportunities-in both replicates of the 720-compound and 1080-compound mixtures, in both replicates of a 3000compound mixture, and 1 replicate of a 1918-compound mixture. Compound 3 was not observed in either replicate of a 2673-compound mixture or a 2878-compound mixture, but it was observed in both positive and negative ion modes of the 720-and 1080-compound mixtures. It met selection criteria in both replicates of the 720-compound mixture but was picked only once in the 1080-compound mixture. Although compounds do not show up in every mixture, these results illustrate that confirmed ligands are identified in mixtures as large as 3000 compounds. Furthermore, compounds with weaker affinity than compound 3 have been detected in screens against other targets using large mixtures (data not shown). Despite a total compound concentration typically in the low millimolar range due to the large number of compounds in a mixture, the low concentration of individual compounds and their diversity in a randomly assembled library minimizes competition between ligands for available sites during the primary screen.
Chk1 hit discovery
Three compounds are shown in Figures 2 and 3 and represent several of the hits that yielded measurable K D values in the ASMS screen of Chk1. They comprise different structural classes, different levels of selectivity, and different activities. Chk1 kinase inhibitory activities of the compounds are shown in Figure 3 , along with the single-point K D estimates. 15 The staurosporine analog, compound 2, has been picked and deconvoluted from all kinase target screens and is a known nonspecific kinase inhibitor. It is very similar to staurosporine and to the staurosporine analog UCN-01, a highly studied Chk1 inhibitor. [16] [17] [18] The benzimidazole compound (compound 3) has 3-b] pyridazine moiety that is similar to a series of compounds characterized for binding to the Akt kinase pleckstrin homology (PH) domain. [19] [20] [21] We have observed no inhibition of enzymatic activity of either full-length or truncated catalytic domain constructs of Akt1 proteins by compound 1 at concentrations up to 50 µM. An X-ray crystal structure of the complex of Chk1 and compound 1 was solved to confirm and elucidate the binding mode of the compound (Fig. 4) . Compound 1 was found in the ATP binding pocket of Chk1. An internal hydrogen bond between the 3-hydroxy group and 1 of the azo-nitrogen atoms keeps the compound almost planar to fit into the cleft. The 2 hydroxy groups of the benzene ring form 2 hydrogen bonds, 1 direct and 1 water mediated, with the CO and NH moieties of Cys 87. The side chain amine group of Lys 38 is within hydrogen bonding distance from 1 of the nitrogen atoms (N1) of the triazole ring of compound 1. Another nitrogen (N2) of the triazole ring makes a hydrogen bond with a water molecule, which forms a water molecule network together with 2 other water molecules nearby. Those 2 nearby water molecules form a hydrogen bond network with neighboring polar groups of Chk1 in this vicinity; these include the carboxyl group of Glu 55, the side chain of Asn 59, the NH group of Phe 148, and the CO of Val 68. The trifluoromethyl group is surrounded by the hydrophobic side chains of 5 nonpolar residues (Ala 36, Val 23, Leu 137, Val 68, and Leu 84). The 5-and 6-position carbons of the benzene ring are exposed to the opening of the ATP binding cleft of Chk1 and are therefore promising modification sites for improving the inhibitory potency and pharmacokinetic properties of the compound.
Chk1 is critical for maintenance of the G2 cell cycle checkpoint in the presence of the DNA damaging agent doxorubicin. Inhibition of Chk1 abrogates the G2 checkpoint and results in a decrease in the G2 population and increase in the number of cells undergoing apoptosis. 12 To determine whether compound 1 inhibits cellular Chk1 activity, H1299 cells were treated with the compound for 3 days and analyzed through fluorescenceactivated cell sorting (FACS). Figure 5A shows that the compound does not change the relative number of cells in various stages of the cell cycle at up to 50 µM concentration in the absence of doxorubicin. In the presence of 500 nM doxorubicin, however, increasing the concentration of the compound to 50 µM reduced the G2 population from 65% to 29% and increased the apoptotic cells from 13% (control) to 37%. These results are consistent with results obtained by using Chk1 siRNA in the presence and absence of doxorubicin. 12 A fraction of the cells from FACS samples also was examined by fluorescence microscopy. Figure 5B shows intact nuclei in DMSO-treated control cells that contain 2 N DNA. Red crosses are the water molecules described in the text. Compound 1 is shown in the ball-and-stick model.
Cells treated with compound 1 alone look identical (data not shown). Cells treated with doxorubicin alone have large (4 N DNA) nuclei. Treatment with a combination of compound 1 and doxorubicin results in fragmentation of the large 4 N nuclei, indicated by the arrows. DNA fragmentation is a typical feature of apoptosis.
DISCUSSION
In less than 2 months, 230,000 small-molecule compounds were screened against multiple targets, and several lead compound series were identified and confirmed by enzymatic assays. The inhibitor series described here were discovered through parallel highly robust and efficient screening processes. As indicated by the data in Table 1 , the process has been applied to 15 kinase targets, yielding confirmed ligands for each. One key to success for this very straightforward screening process is the large number of compounds per primary screening mixture; otherwise, protein consumption would be prohibitive. Although larger compound mixtures result in an increase in mass redundancy and therefore a concomitant increase in the number of compounds required for retesting and deconvolution, the overall efficiency is richly increased. A library subset of 8640 compounds was screened for Chk1 ligands in 20 small orthogonally designed mixtures (same compounds present in 2 different mixtures) and yielded only 36 compounds (0.4% of the library) for retesting. Smaller primary screening mixtures reduced the number of compounds for retesting in part because of decreased mass redundancy within the peaks picked. For the major library (229,157 compounds), larger primary mixtures were screened in duplicate (without orthogonal design). To cover the matched (duplicate) and unmatched compound picks identified would require deconvolution of 3437 compounds. The total number of mixtures would be ~317 (86 duplicate primary mixtures and approximately 145 deconvolution mixtures of 24 compounds each). However, a total of only 202 compound mixtures were used for the major library set because unmatched compounds were excluded from retesting. The potent selective lead compound (compound 1) was discovered through this strategy. If the major library were scaled to the small library strategy, orthogonal mixtures of 720 and 1080 compounds, then 530 total mixtures would be required for the primary screen alone. Although it is possible that some hits may be missed by using our strategy to increase screening efficiency and decrease protein consumption, the results shown here for Chk1 and other targets in Table 1 indicate that the effect of increasing mixture size does not preclude discovery of known and novel compound series.
The efficiency of the hit-picking process is enhanced by automated analysis software. Although peaks in mass spectra that meet various selection criteria can be identified by hand, peaks that stand above the local background (the intrapool criterion) are less likely to be missed when automation is employed because the local signal-to-noise ratio can vary significantly across the m/z range. Furthermore, a key component of the computer program is the ability to simultaneously load all the primary screening spectra for evaluation of whether a peak standing above the local background also stands above the peak intensities at the same m/z position in other spectra (the interpool criterion). This step is very cumbersome to do manually. A second key component is the ability to efficiently compare spectrum peak positions to compound lists and their expected positions in positive and negative ion detection modes. Peaks that appear unique, but do not correspond to any expected compound, are automatically rejected from further consideration. The software uses the compound identity and exact mass information to rapidly match compounds in experimental replicates and allow rapid creation of nonmass redundant deconvolution mixtures. Generally, for primary ASMS screens, compounds matched in replicate primary screens that also meet the quantitative picking criteria were selected for the deconvolution phase of screening. No tagging of the protein or library or other constraints are required for ASMS screening. High efficiency is obtained using very large compound mixtures, whereas binding stringency is controlled by compound and protein concentration and well-defined equilibration volumes and timing steps. Other described ultrafiltration/mass spectrometry studies have not capitalized on the efficiency of large mixtures, the signal-tonoise enhancement from multiple rounds of selection, and/or the ability to rank order ligands by affinity simultaneously with initial ligand identification. 22 The Chk1 inhibitors described here represent both known (compound 2) and novel (compounds 1 and 3) structures. Compound 1 is particularly interesting for 2 reasons. First, it has submicromolar inhibitory activity in Chk1 enzymatic assays and shows specific measurable Chk1 cellular activity, demonstrating a direct connection between small-molecule binding to an isolated protein target and cellular checkpoint abrogation. Second, the triazolo[4,3-b]pyridazine core of compound 1 is present in PH domain-binding Akt inhibitors. 21 However, compound 1 fails to inhibit either catalytic domain or full-length Akt1 proteins (data not shown). The key difference between compound 1 and the Akt1 inhibitors is that all of the latter contain substitutions at position 7 of the pyridazine ring by cycloalkyl, aryl, or phenyl moieties. Therefore, these may be critical for Akt inhibition. Kinase inhibitory activity has not been observed for any kinase yet tested against compound 1 other than Chk1.
Using a highly efficient affinity-based screening process, we describe here a process for screening kinase enzymes against a library of several hundred thousand small-molecule candidates and demonstrate specific novel inhibitors of human Chk1 enzymatic and cellular function. These results show that novel, potent compounds with cellular activity can be discovered and identified directly from very large random compound mixtures simply by mixing the library in solution with purified protein, separating nonligands by ultrafiltration, and identifying ligands by mass spectrometry.
EXPERIMENTAL PROCEDURES
Affinity selection
Human Chk1 was expressed and purified as a recombinant protein in house at Abbott Laboratories (North Chicago, IL) from a construct previously published, [Chk1 (289 aa)]-6His. 11 Other kinase enzymes were prepared by standard methods. Highperformance liquid chromatography (HPLC)-grade water, methylene chloride, and methanol were purchased from EM Science (Gibbstown, NJ). Potassium chloride and Tris solution were purchased from Gibco BRL (Grand Island, NY). Known kinase inhibitors were purchased from Calbiochem. Kinase enzymes were screened at a concentration of 10 µM, and the individual compounds in the mixture pools in primary screening were present at 1.5 µM. Primary kinase screens were run twice, and compounds identified twice (in both replicates) were carried forward to the retesting and deconvolution phase. Compound mixtures were prepared and screening carried out essentially as described. 15 In brief, random mixtures of 1800 to 3000 defined smallmolecule candidates were prepared in 100% DMSO at concentrations of 20 to 40 µM each compound. The compound mixtures were diluted for ASMS screening into buffer containing 50 mM Tris-HCl (pH 7.5), 200 mM KCl, and 5 mM DTT, along with Chk1 at 10 µM, and allowed to equilibrate for 30 min at room temperature, then subjected to 3 rounds of ultrafiltration in a Millipore Microcon-10 units with buffer addback and reequilibration between rounds. Chk1 protein was added back between rounds of ultrafiltration at 10% of the initial concentration. The final retentate containing Chk1 protein and selected ligands was subjected to organic solvent extraction to remove buffers and protein, followed by electrospray ionization/time-of-flight (ESI-TOF) mass spectrometry using a Micromass LCT Classic as described. 15 A mass range of 150 to 900 amu was scanned rather than 200 to 800 as before. To maintain the mass calibration of the instruments, a 5-compound mixture spanning the mass range was tested before and after each day's set of samples. If necessary, mass calibration was done before sample analysis. Mass accuracy of 0.1 m/z units or better was achieved, and the ASAE.NET software offers a further postacquisition calibration as described below.
ASMS data analysis
A macro program for Microsoft Excel (outputV8.xls) was written at Abbott, allowing conversion of the peak lists from multiple spectra generated by the Masslynx software (Waters, Milford, MA) to be collected into a single text file for importing into ASAE.NET software. ASAE.NET is a proprietary software program created for Windows NT and 2000 operating systems. To prepare files for import, the Microsoft Excel macro outputV8.xls was used to integrate spectra from the Masslynx software package over a defined time period and produce text file lists of m/z ratios and intensities. Generally, one 96-well plate of samples and controls was used to create a single text file of approximately 34 MB size. The ASAE.NET program uses the sample file, a static list of exact masses of all candidate ligands and their mixture assignments, and user-defined criteria to automatically pick peaks most likely to contain ligands. The data also are displayed for visual inspection, in order to potentially reject auto-selected picks, make new picks, and evaluate the quality of retest data. Results of the analyses were automatically incorporated into the Oracle tables of a Web-based database, also developed at Abbott.
